ArticleScientific reports2025
Prognostic impact of tertiary lymphoid structures and cancer-associated fibroblasts in hepatocellular carcinoma with portal vein tumor thrombus.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Immunogenic cell death and tertiary lymphoid structures: bridging tumour cell death and immune organization.Nature reviews. Immunology · 2026Review
- Beyond TLS Presence: A Functional Framework Integrating Maturity, Location, and Immune Context.Cancers · 2026Review
- KLRB1 gene in tumor immune regulation and disease prognosis: a multidimensional role review.Discover oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The significance of tertiary lymphoid structures (TLS) in hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) remains ambiguous. This study evaluates the prognostic impact of intra-tumoral TLS (iTLS) and peri-tumoral TLS (pTLS) and explores the interplay between TLS and cancer-associated fibroblasts (CAF) in patients undergoing curative hepatic resection. A retrospective analysis of 83 HCC patients with PVTT assessed the prognostic value of TLS. Transcriptomic data were mined to identify TLS- and CAF-related genes, and a seven-gene prognostic model was constructed using LASSO and Cox regression analyses. Immune microenvironment, mutation characteristics, and response to immunotherapy were analyzed between risk groups. iTLS + and high pTLS density were independently associated with improved overall survival (OS), but not recurrence-free survival (RFS) or early recurrence. A novel risk model comprising KLF2, HBEGF, KLRB1, PGF, JAM2, CHORDC1, and YTHDF2 stratified patients into high- and low-risk groups, with the high-risk group demonstrating poorer OS and diminished immunotherapy responsiveness. Low-risk patients exhibited higher immune infiltration (e.g., B cells, T cells) and stronger antitumor activity, whereas high-risk tumors showed active proliferation and immune evasion. iTLS and pTLS are independent predictors of favorable OS in HCC patients with PVTT. The TLS/CAF-based risk model offers robust prognostic utility and highlights distinct biological and immune features between patient subgroups. These findings provide a foundation for personalized prognostic assessment and therapeutic decision-making in advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.